Families affected by Pharmac's decision to switch brands of Epilepsy drug say they have had no say in a report into the drug buying agencies processes, and are insulted by its findings.
The review, which was commissioned by Pharmac, found its processes were of a high standard but it should have consulted its consumer advisory group.
It comes as the Chief Coroner has confirmed to RNZ that she's investigating whether a seventh death is linked to patients being switched to a generic anti-epilepsy drug called Logem.
And a doctor who deals with epileptic children has come forward saying Pharmac is forcing her to start children on the generic drug - which she is deeply uncomfortable with given the coroner's findings have not yet been released.
Investigative journalist Guyon Espiner has been covering the issue for more than a year and filed this report.
